Start the conversation
Our "Best Bargain in Biotech" stock is on the move again.
Back on Jan. 10, we recommended that you take another look at European "Baby Biotech Galapagos NV (OTC ADR: GLPYY). Galapagos was the very first stock that we recommended on the very first day that we published Private Briefing more than two years ago, and it subsequently soared as much as 214%.
It backtracked a bit last year, but then demonstrated some real muscle by holding the line when other biotechs sold off as 2013 came to a close. It was so resistant to a biotech-sector sell-off, in fact, that we re-recommended it in early January, and then again at the end of the month. Full Story
This is premium content for Private Briefing subscribers only.